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Acute myeloid leukemia (AML) is a heterogeneous group of diseases in which chromosomal aberrations,
small insertions or deletions, or point mutations in certain genes have profound consequences for prognosis.
However, the majority of AML patients present without currently known genetic defects. Retroviral insertion
mutagenesis in mice has become a powerful tool for identifying new disease genes involved in the pathogenesis
of leukemia and lymphoma. Here we have used the Graffi-1.4 strain of murine leukemia virus, which causes
predominantly AML, in a screen to identify novel genes involved in the pathogenesis of this disease. We report
79 candidate disease genes in common integration sites (CISs) and 15 genes whose family members previously
were found to be affected in other studies. The majority of the identified sequences (60%) were not found in
lymphomas and monocytic leukemias in previous screens, suggesting a specific involvement in AML. Although
most of the virus integrations occurred in or near the 5 or 3 ends of the genes, suggesting deregulation of gene
expression as a consequence of virus integration, 18 CISs were located exclusively within the genes, conceivably
causing gene disruption.
Acute myeloid leukemia (AML) is characterized by a block
in myeloid differentiation that results in the accumulation of
leukemic myeloid cells in the bone marrow and peripheral
blood. For AML cases with specific chromosomal transloca-
tions, the identification and functional characterization of fu-
sion genes located at translocation breakpoints have resulted
in the discovery of pathways involved in leukemic transforma-
tion (34). However, it also has become clear that these defects
themselves are not sufficient to cause acute leukemia, support-
ing the theory that the disruption of multiple regulatory mech-
anisms is required to fully transform hematopoietic stem and
progenitor cells toward AML. At present, cytogenetic param-
eters are used successfully in clinics for risk stratification of
leukemia. For instance, AML cases with t(8;21), t(15;17), and
inv(16) chromosomal abnormalities are classified as low risk,
whereas cases with 3q26, 5q, and 7q abnormalities generally
are classified as high risk, with unfavorable treatment out-
comes resulting in early relapse and decreased overall survival
(34, 47). Importantly, for the majority of AML cases (60%),
tentatively classified as intermediate risk, the genetic parame-
ters predictive for therapy outcome have not been identified
(14, 15). Furthermore, in the approximately 20 to 40% of AML
patients without chromosomal abnormalities, the molecular
pathogenesis remains entirely unknown (33).
Retroviral insertion mutagenesis in mice has become a pow-
erful and rapid method for the identification of new genes
involved in cancer (23). This approach has benefitted greatly
from both human and mouse genome programs and the re-
cently developed genome database search programs (20, 29).
Studies aimed at finding novel genes involved in leukemia thus
far have been carried out with virus strains that have a pro-
pensity to induce lymphoid malignancies or myelomonocytic
tumors (21, 26, 32, 37, 44, 54). To focus this strategy on my-
eloid leukemia, we have used the Graffi-1.4 (Gr-1.4) virus,
which has been demonstrated to induce leukemia with pre-
dominantly myeloid or mixed-lineage early hematopoietic phe-
notypes (9, 48). As with the Moloney and Cas-Br-M viruses
used in previous studies, the Gr-1.4 virus does not contain
oncogenic sequences but can deregulate or disrupt gene ex-
pression due to proviral integration.
Recently, Erkeland et al. reported on a new Gr-1.4 virus
common integration site (CIS) that is located in the Yin Yang
1 (YY1) promoter and that causes the deregulation of YY1
gene expression, resulting in defective myeloid differentiation
(9). Here we report 94 candidate leukemia disease genes that
are targeted by the Gr-1.4 virus. While some of the affected
genes in the Gr-1.4 virus-induced leukemia overlapped with
those identified in lymphoma screens, suggesting a more gen-
eral involvement in leukemogenesis and lymphogenesis, the
majority of integrations appeared to affect novel genes that
may be more specifically involved in the development of my-
eloid malignancies.
MATERIALS AND METHODS
MuLV Gr-1.4-induced leukemia. Newborn mice were injected subcutaneously
with 100 l of cell culture supernatant from murine leukemia virus (MuLV)
Gr-1.4-producing NIH 3T3 cells (a gift from E. Rassart, Department des Sci-
ences Biologiques, Universite du Quebec a` Montreal, Montreal, Quebec, Can-
ada). Mice were treated and analyzed for the development of leukemia as
previously described (9). Chromosomal DNA was isolated from leukemic cells
for PCR-based screening (9).
Cytological analysis and immunophenotyping of leukemic cells. For morpho-
logical analysis, blood smears and cytospin preparations were fixed in methanol,
stained with May-Gru¨nwald-Giemsa stained, and examined by using an Axio-
scope microscope (Carl Zeiss BV, Weesp, The Netherlands). Single-cell suspen-
sions of different organs were analyzed by flow cytometry with a FACScan flow
cytometer (Becton Dickinson and Co., Mountain View, Calif.). Cells were la-
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beled as described previously (25) with the following rat monoclonal antibodies:
ER-MP54, ER-MP58, M1/70 (Mac-1), F4/80, RB68C5 (GR-1), ER-MP21
(transferrin receptor), TER119 (glycophorin A), 59-AD2.2 (Thy-1), KT3 (CD3),
RA3 6B2 (B220), and E13 161-7 (Sca1). Immunodetection was performed with
goat anti-rat antibodies coupled to fluorescein isothiocyanate (Nordic, Tilburg,
The Netherlands).
Inverse PCR of MuLV Gr-1.4-induced leukemia. The inverse PCR strategy
was recently described in detail (9). Briefly, genomic DNA from primary tumors
was digested with HhaI (CGCG). After circularization by ligation (rapid ligation
kit; Roche Diagnostics, Mannheim, Germany), an initial PCR was performed
with MuLV Gr-1.4 (long terminal repeat [LTR])-specific primers L1 (5-TGCA
AGATGGCGTTACTGTAGCTAG-3) and L2 (5-CCAGGTTGCCCCAAAG
ACCTG-3). Cycling conditions were 1 min at 94°C, 1 min at 62°C, and 3 min at
72°C for 30 cycles. For the second, nested PCR, primers L1N (5-AGCCTTAT
GGTGGGGTCTTTC-3) and L2N (5-AAAGACCTGAAACGACCTTGC-3)
(15 cycles) were used. The PCR mixture contained 10 mM Tris-HCl (pH 8.3), 50
mM KCl, 1.5 mM MgCl2, 200 M deoxynucleoside triphosphates, 10 pmol of
each primer, and 2.5 U of Taq polymerase (Pharmacia, Uppsala, Sweden). The
PCR fragments were analyzed on a 1% agarose gel.
Detection of virus integration by a specific nested PCR. To determine the
localization of the Gr-1.4 provirus in specific virus-targeted genes in an extended
panel of leukemias, a nested PCR was performed with DNA from primary
tumors. For the first PCR, virus integration site locus-specific primers X1 and X2
were used in combination with MuLV Gr-1.4 LTR-specific primers L1 and L2
(Fig. 1). Cycling conditions were 1 min at 94°C, 1 min at 62°C, and 3 min at 72°C
for 30 cycles. For the second PCR, nested virus integration site-specific primers
X1N and X2N were used in combination with nested LTR-specific primers L1N
and L2N under the same conditions (Fig. 1). The PCR products obtained were
analyzed by Southern blotting. To verify the correct nature of the amplified
bands, the blots were hybridized with radiolabeled gene-specific probes P1 and
P2 (Fig. 1) at 45°C in Church buffer (0.5 M phosphate buffer [pH 7.2], 7%
[wt/vol] sodium dodecyl sulfate, 10 mM EDTA) overnight. Signals were visual-
ized by autoradiography according to standard procedures (34a).
Nucleotide sequence analysis. PCR products were sequenced by using an ABI
3100 sequencer (Applied Biosystems, Neuwerkerk aan den Ijssel, The Nether-
lands) with MuLV Gr-1.4-specific forward primer L1. Virus flanking genomic
sequences were analyzed by using GenBank (National Center for Biotechnology
Information), a Celera discovery system (Celera Genomics, Rockville, Md.) (19,
29), and Ensembl (Wellcome Trust Genome Campus, Hinxton, Cambridgeshire,
United Kingdom) (20).
RESULTS
Gr-1.4-induced leukemias. Eighty-nine newborn FVB/N
mice were inoculated with Gr-1.4. When moribund, mice were
sacrificed, and hematopoietic organs were isolated. Six mice
died without signs of leukemia and were excluded from further
investigation. Standard blood cell analysis was performed, and
values were compared with the mean value for 10 normal
FVB/N mice (24). Most of the leukemic mice had increased
numbers of peripheral white blood cells and decreased num-
bers of platelets and red blood cells compared to normal con-
trols (data not shown). Blast percentages in the bone marrow
ranged from 24 to 90%, with an average of 48%. Leukemic
cells from 76 mice were immunophenotyped. The major im-
munophenotypic features of these leukemias are given in Ta-
ble 1. Based on these criteria, the leukemias were classified as
T-lymphoid; mixed lymphoid, erythroid, and myeloid; myeloid;
myelomonocytic; or erythroid. Fifty-nine leukemias were ana-
lyzed morphologically. Representative examples are shown in
Fig. 2. Almost all of the mice showed splenomegaly, with 25%
showing thymus enlargement, 20% showing lymph node en-
largement, and 55% showing liver involvement. In 5% of the
mice, leukemic cells were present in the bone marrow and
blood, without overt peripheral organ involvement.
Virus integration sites in Gr-1.4-induced leukemias. PCR
analysis in conjunction with database searches identified a total
of 94 different virus integration sites out of 69 tumors, 38 of
which were found in earlier screens. Examples of this latter
FIG. 1. Directed PCR of chromosomal DNA to determine the commonality of virus integration sites (VIS) identified by inverse PCR. Primers
X1, X1N, X2, and X2N were designed from a locus that was identified as a virus integration site by inverse PCR. To amplify flanking genomic
sequences and to determine the localization and orientation of the integrated provirus, four different nested PCRs were performed. First, primers
X1 and X2 were combined with MuLV Gr-1.4 LTR primers L1 and L2. The products were amplified by a nested PCR with primers X1N and X2N
in combination with L1N and L2N. The specificity of the amplified bands was checked by Southern blot analysis with probes P1 and P2.
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group of CISs are p53 (39, 41), Notch-1 (12, 13, 31), Evi-1 (38),
NF1 (Evi-2) (5), Lck-1 (1, 11, 35), Pim-1 (50), HoxA9 (Evi-6)
(43), Fli-1 (4, 8), and N-Myc (18, 51). Notably, 79 of the 94
integrations were CISs, directly implicating the affected genes
in leukemic transformation. The remaining 15 were included in
this report because family members closely related to these
genes were found in other studies. Fifty-six of the identified
sequences were mapped near or in novel candidate leukemia
genes. The products of the affected genes have been classified
as receptors and signaling molecules (Table 2), as regulators of
transcription (Table 3), and as having regulatory roles in other
pathways (e.g., DNA stability and proteasomal targeting) or
unknown functions (Table 4).
Approximately 15% of the virus integrations identified by
this inverse PCR-based screen were determined to be common
(more than two integrations in a particular genomic locus) by
the initial screen. To determine the frequency of common
integrations more sensitively, we performed integration-spe-
cific PCRs with 49 Gr-1.4-targeted genes in multiple tumors
(Tables 2 to 4); most appeared to be common. We sequenced
the integrations in 19 genes derived from multiple (2 to 10)
tumors; these included VDUP1, PrdxII, 11- to 19-lysine-rich
leukemia (ELL), promyelocytic leukemia zinc finger (PLZF),
and Edg3. In all instances, the integrations were located in the
expected gene but at different positions, confirming the spec-
ificity of the Southern analysis and ruling out the possibility of
cross-contamination by previously amplified PCR products.
The genes flanking the virus integration sites were compared
with data from the National Cancer Institute retrovirus-tagged
cancer gene database (RTCGD) at http://genome2.ncifcrf.gov
FIG. 2. Morphological features of MuLV Gr-1.4-induced leukemia. Micrographs were taken with a Zeiss Axioscope microscope (magnification,
1,000). Morphological subtypes were lymphoblasts (I); mixed erythroblasts, myeloblasts, and lymphoblasts (II); myeloblasts (III); myelo-
monoblasts (IV); and erythroblasts (V).
TABLE 1. Gr-1.4-induced leukemiasa
Subtype Leukemia type Immunophenotype (markers) No. ofleukemias
I T-lymphoid MP21 CD3 Thy1 2
II Mixed lymphoid, erythroid, and myeloid differentiation Gr1 F4/80 Mac1 Imm CD3 B220 (gcsfr
Ter119)
12
III Myeloid differentiation 1mm MP21 (F4/80 Gr1 B220 Mac1
gcsfr)
43
IV Myelocytic or monocytic 1mm Gr1 gcsfr (F4/80 Mac1 B220) 15
V Erythroid Ter119, MP21 (Sca1) 4
Total 76
a All tumors were tested with the markers MP21, MP58, CD3, Thy1, Gr1, F4/80, Mac1, Sca1, B220, Ter119, and gcsfr. Markers that were consistently negative are
not shown, unless they were informative for discrimination between myeloid subtypes III and IV. Imm indicates positive staining for immature hematopoietic cell
markers Sca1, MP58, and MP54 (Thy1). Markers in parentheses were not present in all individual tumors.
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and other sources (Tables 2 to 4). The Gr-1.4 integrations that
are included in this database or that were reported in other
studies are indicated by the database name or references in
Tables 2 to 4. Family members of Gr-1.4-targeted genes found
in other studies are also indicated in those tables. Most of the
virus integrations occurred in or near the 5 or 3 ends of the
genes, suggesting that the levels of expression of these genes
are deregulated as a consequence of virus integration. Eigh-
teen CISs were located exclusively within the gene, conceivably
causing gene disruption. This group comprises the previously
reported virus targets Notch-1, NF1, PTPN1, Inpp4a, p53,
SWAP70, and Kcnk5 and 11 new virus targets: calcyphosine,
phosphodiesterase 1, ELL, NCOR-1, HDAC-7A, histone
H3.3A, Api-5, Ril, D6Mm5e, and two unknown genes.
DISCUSSION
In this study, we have used in vivo retroviral mutagenesis
with the Gr-1.4 virus complex to identify novel disease genes
specifically involved in the pathogenesis of AML. In compara-
ble studies with other virus strains, e.g., Moloney, AKXD, or
Cas-Br-M, the most prominently appearing tumor types are T-
and B-cell lymphomas; in the case of BXH2, myelomonocytic
tumors are prominent (21, 30, 32, 37, 54). In contrast, more
than 80% of the leukemias induced by Gr-1.4 unequivocally
exhibited immunophenotypic characteristics of myeloid cells,
with immature morphological features (mainly myeloblasts),
emphasizing the unique features of the Gr-1.4 virus complex as
a tool for characterizing pathogenetic mechanisms in myeloid
disease. Indeed, the majority of the CISs described here have
thus far not been reported in extensive screens in lymphoma
models, although some overlap was observed. The latter ob-
servation is not surprising in view of the fact that cell type-
specific events usually impinge on downstream common regu-
latory pathways that can be affected in multiple tumor types.
Although most of the Gr-1.4 CISs have been linked to can-
didate disease genes based on their proximity to these genes,
proviral integrations have been reported to influence gene
expression over distances of more than 100 kb. Thus, we can-
not exclude the possibilities that genes located more distantly
from the CISs also are deregulated and that multiple genes are
affected by a single CIS (44). In addition, three other aspects of
retroviral screens as they are currently being performed must
be emphasized. First, malignancies induced by replication-
competent retroviruses are usually oligo- or polyclonal rather
than monoclonal (9, 32). Although this characteristic gives rise
to high frequencies of CISs in relatively small cohorts of mice,
it complicates the search for cooperating events within one
leukemic clone. Second, the sensitive PCR-based techniques
used to identify virus integrations do not allow distinction
between CISs present in a majority of the leukemic cells, ini-
tiating an early pathogenic event, and CISs present in only a
minor population of the cells, probably affecting leukemia pro-
gression genes. Finally, a recent study emphasized that MuLV
strains have a preference for integration near transcriptional
start sites (62). Our data obtained with Gr-1.4 corroborate
these conclusions and indicate that retroviral mutagenesis with
MuLV preferentially, although not exclusively, identifies gene
deregulation rather than gene disruption. Another importantPr
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conclusion drawn by Wu and colleagues is that there appear to
be no integration hot spots (preferred integration sites in cer-
tain loci) for MuLV (62). Therefore, CISs found in viral
screens are likely to play a role in leukemia.
Many of the Gr-1.4-affected genes appeared to be related to
signaling; some have been linked to human leukemia already.
For instance, the Tie-1 gene, which encodes a tyrosine kinase
receptor that is normally expressed in vascular endothelial cells
and hematopoietic stem cells, is overexpressed in chronic my-
eloid leukemia (59). Importantly, high Tie-1 levels inversely
correlate with the survival of chronic myeloid leukemia pa-
tients in the early chronic phase (59). Markedly increased
levels of Tie-1 also were detected in bone marrow samples
from myelodysplastic syndrome and AML patients (58).
Notch-1 is another example of a CIS associated with human
disease. The human homologue of the Notch (Tan-1) gene is
involved in chromosomal translocation t(7;9)(q34;34.3), which
results in a truncated receptor in human T-lymphoblastic neo-
plasms. Notch-1 is a proviral integration site in mouse lym-
phoid leukemias (12, 31). Our data suggest that aberrant
Notch signaling also may be involved in myeloid leukemia.
Notably, the integrations in the Notch gene result in the con-
stitutive formation of the truncated active form of Notch (31),
which has been demonstrated to interfere with granulocyte
colony-stimulating factor-induced myeloid differentiation in
the 32D cell model (55). Edg3 (endothelial differentiation gene
3) is a G-protein-coupled receptor (GPCR) involved in cell
proliferation and survival (2). The expression of Edg3 is down-
regulated during the differentiation of HL60 human leukemia
cells and is assumed to mediate sphingosine 1-phosphate-in-
duced Ca2 responses (49). Although the role of Edg receptors
in normal hematopoiesis and malignancies is not yet clear, a
closely related GPCR, cannabinoid receptor type 2, was found
in a CIS in Cas-Br-M-induced leukemia (57). Notably, per-
turbed expression of cannabinoid receptor type 2 recently was
found to interfere with myeloid differentiation, supporting the
notion that this type of GPCR may contribute to the patho-
genesis of AML by inducing a maturation block (27).
Both protein and lipid phosphatases are crucial, mostly neg-
ative, regulators in growth factor signaling pathways (7, 64).
Two members of the protein tyrosine phosphatase nonreceptor
(PTPN) family affected by Gr-1.4 are PTPN1 and PTPN5. The
virus integrations in the PTPN1 gene are localized in intron 1
and conceivably disrupt its function. The PTPN1 gene was
found in a CIS in BXH2-induced leukemia (32). Because
TYK2, JAK2, and STAT5—JAK/STAT signaling intermedi-
ates involved in growth control by hematopoietic growth fac-
tors—are all inactivated by PTPN1 (also known as PTP1B) (3,
16, 42), the disruption of PTPN1 is predicted to contribute to
uncontrolled proliferation and survival of leukemic cells. Inte-
grations in the PTPN5 gene occur in exon 1, upstream of the
ATG translation start site. At present, little is known regarding
the signaling function of PTPN5, which is alternatively termed
STEP. Interestingly, recent data suggest that PTPN5/STEP
shows a preferential affinity for p38 mitogen-activated protein
kinase in a redox-sensitive manner, leaving the Erk kinases
largely unaffected (40). Inhibition of p38 mitogen-activated
protein kinase activity by pharmacological inhibitors has been
shown to interfere with terminal neutrophilic differentiation
(G.-J. van de Geijn et al., unpublished data) and to prevent
apoptosis in neutrophils (10). Conceivably, dephosphorylation
of p38 by PTPN5/STEP may have similar effects and may
promote the survival of immature myeloid cells. Other phos-
phatases that are targeted by Gr-1.4 are the inositol polypho-
sphate phosphatases Inpp4a and Inpp5b, which catalyze the
hydrolysis of phosphatidylinositol polyphosphates at positions
4 and 5, respectively. Intriguingly, Inpp4a is a major target for
transcription factor GATA-1 and inhibits the growth of
megakaryocytes and NIH 3T3 fibroblasts (60). Inpp5b is re-
quired for normal sperm development and function (17), but
how this enzyme affects normal or leukemic blood cell devel-
opment is not known.
Reactive oxidant species (ROS) are generated by multiple
cellular mechanisms, including metabolic processes, phago-
cytic reponses to pathogens (oxidative burst), and membrane
receptor-mediated signaling. The tight regulation of ROS con-
centrations in the cell is controlled by both catabolic and redox
mechanisms and is important for signal transduction, as it
influences protein kinase and phosphatase reactions as well as
the activities of transcription factors (46). When ROS levels in
a cell are too high, the resulting oxidative stress will affect
normal protein function and genomic stability (46). Genes
involved in the redox-controlled regulation of ROS levels that
are commonly targeted by Gr-1.4 are those for vitamin D3-
upregulated protein 1 (VDUP1) and peroxiredoxin 2 (PrdxII).
VDUP1 interacts with thioredoxin (TRX) and thereby coun-
teracts the ameliorating effects of TRX on stress-induced ap-
optosis via apoptosis signal-regulating kinase 1 (ASK-1) and
the function of TRX as an antioxidant (28). The consequence
of upregulation of PrdxII is as yet unclear, but it may interfere
with the function of peroxiredoxin complexes and therefore
inhibit the antistress activities of TRX (6). Importantly, PrdxII
is a TRX reductase and has been found to be overexpressed in
human breast cancer (45).
The ELL and PLZF genes are two examples of genes that
are part of fusion genes in human AML as a result of chro-
mosomal translocations. In translocation t(11;19)(q23;p13.1),
the ELL gene is fused to the trithorax-like mixed lineage leu-
kemia (MLL) gene (56). The ELL protein is an RNA poly-
merase II elongation factor (53). Recently, it was demon-
strated that both MLL-ELL and ELL inhibit p53 activity via
binding of the C-terminal part of ELL to the transactivating
domain of p53 (61). The PLZF gene, involved in translocation
t(11;17)(q23;q21), is fused in frame with RAR (22, 36). PLZF
is expressed in hematopoietic stem cells and normally is down-
regulated during differentiation. The overexpression of PLZF
plays a role in the maintenance of the immature state of he-
matopoietic progenitor cells and promotes cell survival (52,
63). The fact that PLZF is found as a common Gr-1.4-targeted
gene indicates that the deregulation of PLZF expression can
contribute to leukemic development independent of its fusion
to RAR. One of the major features of PLZF is its tight
binding to transcriptional corepressors. Interestingly, several
genes involved in transcriptional repression by chromatin mod-
ification, such as those for N-Cor-1 and histone deacetylases
HDAC1 and HDAC7, are affected by Gr-1.4. Notably, family
members of these proteins (N-Cor-2 and HDAC5) also were
found in previous screens (54)
In conclusion, using high-throughput retroviral screens with
the Gr-1.4 virus complex, we have identified novel pathways
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involved in myeloid leukemia. Currently, we are studying the
consequences of aberrant gene expression or function by using
gene transfer methodology with 32D cells and primary bone
marrow cultures (9). In addition, we are analyzing the signifi-
cance of these pathways for human AML by screening expres-
sion levels in a panel of clinical samples with a gene expression
array and quantitative reverse transcription-PCR technology.
By following this combinatorial approach, we hope to develop
new prognostic indicators that will discriminate further be-
tween low and high responses to therapy in different risk
groups. Furthermore, the results obtained may open new ave-
nues for developing specific and sensitive therapies based on
the heterogeneous pathogenetic features of human AML.
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